To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

The nonerythropoietic asi… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

The nonerythropoietic asialoerythropoietin protects against neonatal hypoxia-ischemia as potently as erythropoietin.

Journal article
Authors Xiaoyang Wang
Changlian Zhu
Xinhua Wang
Jens Gammeltoft Gerwien
Andre Schrattenholz
Mats Sandberg
Marcel Leist
Klas Blomgren
Published in Journal of neurochemistry
Volume 91
Issue 4
Pages 900-10
ISSN 0022-3042
Publication year 2004
Published at Institute of Physiology and Pharmacology, Dept of Medical Biophysics
Institute for the Health of Women and Children, Dept of Paediatrics
Institute of Physiology and Pharmacology, Dept of Physiology
Pages 900-10
Language en
Links dx.doi.org/10.1111/j.1471-4159.2004...
Keywords Animals, Animals, Newborn, Asialoglycoproteins, biosynthesis, blood, pharmacokinetics, therapeutic use, Brain Infarction, pathology, prevention & control, Disease Models, Animal, Erythropoietin, analogs & derivatives, biosynthesis, blood, pharmacokinetics, therapeutic use, Female, Hypoxia-Ischemia, Brain, drug therapy, pathology, Male, Membrane Proteins, metabolism, Nerve Tissue Proteins, metabolism, Proteomics, methods, Rats, Rats, Wistar, Signal Transduction, drug effects, Synaptosomal-Associated Protein 25, Treatment Outcome
Subject categories Medical and Health Sciences

Abstract

Recently, erythropoietin (EPO) and the nonerythropoietic derivative asialoEPO have been linked to tissue protection in the nervous system. In this study, we tested their effects in a model of neonatal hypoxia-ischemia (HI) in 7-day-old rats (unilateral carotid ligation and exposure to 7.7% O(2) for 50 min). EPO (10 U/g body weight = 80 ng/g; n = 24), asialoEPO (80 ng/g; n = 23) or vehicle (phosphate-buffered saline with 0.1% human serum albumin; n = 24) was injected intraperitoneally 4 h before HI. Both drugs were protective, as judged by measuring the infarct volumes, neuropathological score and gross morphological score. The infarct volumes were significantly reduced by both EPO (52%) and asialoEPO (55%) treatment, even though the plasma levels of asialoEPO had dropped below the detection limit (1 pm) at the onset of HI, while those of EPO were in the nanomolar range. Thus, a brief trigger by asialoEPO before the insult appears to be sufficient for protection. Proteomics analysis after asialoEPO treatment alone (no HI) revealed at least one differentially up-regulated protein, synaptosome-associated protein of 25 kDa (SNAP-25). Activation (phosphorylation) of ERK was significantly reduced in asialoEPO-treated animals after HI. EPO and the nonerythropoietic asialoEPO both provided significant and equal neuroprotection when administered 4 h prior to HI in 7-day-old rats. The protection might be related to reduced ERK activation and up-regulation of SNAP-25.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?